Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 2, 2014, Pages 209-216

  Bichoupan, K ^a   Schwartz, J M ^b   Martel Laferriere, V ^a   Giannattasio, E R ^b   Marfo, K ^b   Odin, J A ^a   Liu, L U ^a   Schiano, T D ^a   Perumalswami, P ^a   Bansal, M ^a   Gaglio, P J ^b   Kalia, H ^b   Dieterich, D T ^a   Branch, A D ^a   Reinus, J F ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ACUTE APPENDICITIS; ADULT; AGING; ANEMIA; ARTICLE; BODY MASS; COLITIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DERMATITIS; DIABETES MELLITUS; DRUG WITHDRAWAL; DYSPNEA; ETHNICITY; FAINTNESS; FATIGUE; FEMALE; GENOTYPE; HEART ARRHYTHMIA; HEPATITIS C; HISPANIC; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERKALEMIA; HYPOKALEMIA; INFECTION; INTENTION TO TREAT ANALYSIS; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MILD RENAL IMPAIRMENT; PARESTHESIA; PRIORITY JOURNAL; RECTUM DISEASE; RELAPSE; RISK FACTOR; SEX DIFFERENCE; SKIN BURNING SENSATION; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PLATELET COUNT; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84890447516     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12560     Document Type: Article

References (29)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
2. Davis GL, Albright JE, Cook SF, Rosenberg DM,. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
3. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
6. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
7. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
8. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
9. Feuerstadt P, Bunim AL, Garcia H, et al,. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2010; 51: 1137-43.
10. Ghosal A, Yuan Y, Tong W, et al,. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011; 39: 510-21.
11. Sterling RK, Lissen E, Clumeck N, et al,. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
12. Vallet-Pichard A, Mallet V, Nalpas B, et al,. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
13. Benson K, Hartz AJ,. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-86.
14. Hu CC, Lin CL, Kuo YL, et al,. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther 2013; 37: 81-90.
15. Chayama K, Hayes CN, Abe H, et al,. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 84-93.
16. Serfaty L, Forns X, Goeser T, et al,. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012; 61: 1473-80.
17. Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE,. The incidence, predictors and management of anaemia and its association with virological response in HCV/HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther 2011; 33: 1234-44.
18. Canonico PG, Kastello MD, Spears CT, Brown JR, Jackson EA, Jenkins DE,. Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984; 74: 155-62.
19. De Franceschi L, Fattovich G, Turrini F, et al,. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
20. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R,. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepatitis 2004; 11: 243-50.
21. Yoneyama K, Miyagishi K, Kiuchi Y, Shibata M, Mitamura K,. Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. J Gastroenterol 2002; 37: 1028-34.
22. O'Keefe SJ, El-Zayadi AR, Carraher TE, Davis M, Williams R,. Malnutrition and immuno-incompetence in patients with liver disease. Lancet 1980; 2: 615-7.
23. Brennan BJ, Morcos PN, Wang K, et al,. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther 2012; 35: 1209-20.
24. Srivastava S, Bertagnolli M, Lewis JH,. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naive patients in a university liver clinic. J Natl Med Assoc 2005; 97: 1703-7.
25. Conjeevaram HS, Fried MW, Jeffers LJ, et al,. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7.
26. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ,. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163-8.
27. Hezode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-41.
28. Fontaine H, Hezode C, Dorival C, et al,. 60 SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC). J Hepatol 2013; 58: S27.
29. Razavi H, Elkhoury AC, Elbasha E, et al,. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164-70.